|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.68 USD | -3.45% |
|
-6.64% | -3.90% |
| 17/04 | Sarepta Therapeutics Seen Benefiting From New Elevidys Study, Better US Uptake in Second Half of 2026 | MT |
| 16/04 | Roche Plans New Trial for Muscular Dystrophy Therapy to Seek EU Approval | DJ |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 23 | |||||||
| 20 | |||||||
| Average | 22 | |||||||
| Weighted average by Cap. | 21 |
- Stock Market
- Equities
- SRPT Stock
- Sector Sarepta Therapeutics, Inc.
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition